P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.

We studied the resistance of colon tumors to anticancer agents in vitro. Using daunorubicin (DN), a number of cellular parameters which normally indicate acquired or multidrug resistance (MDR), were compared for several human wild-type colon cell lines, i.e. HT29, SW1116 and COLO 320, and the murine colon cell line C-26. The sensitive/MDR human ovarian cancer cell line couple A2780/2780AD was used as a reference. The amount of P-glycoprotein (P-gp) was in the order HT29, A2780 less than or equal to SW1116 less than C26 less than or equal to COLO 320 less than 2780AD. The MDR modifiers verapamil, Cremophor EL, cyclosporin A and Ro 11-2933/001 had significant effects on DN cytotoxicity, total DN accumulation and efflux, only if P-gp was present. A flow-through system was used to study the mechanism of DN transport. For the first time, evidence for saturation of an active transport of DN from the cells is reported. We discussed the possible presence of cooperative activity between at least two binding sites on the protein responsible for DN efflux, likely to be P-gp.

[1]  J. Endicott,et al.  The biochemistry of P-glycoprotein-mediated multidrug resistance. , 1989, Annual review of biochemistry.

[2]  R. C. Bohinski.  Modern concepts in biochemistry , 1976 .

[3]  G. Rimmelzwaan,et al.  Production of monoclonal antibodies defining guinea pig T-cell surface markers and a strain 13 Ia-like antigen: the value of immunohistological screening. , 1985, Hybridoma.

[4]  J. Lankelma,et al.  Immunohistochemical detection of P‐glycoprotein in human tumor cells with a low degree of drug resistance , 1989, International journal of cancer.

[5]  H. H. Lloyd,et al.  Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells. , 1978, Seminars in hematology.

[6]  T. Skovsgaard.  Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. , 1977, Biochemical pharmacology.

[7]  W. Klohs,et al.  Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells. , 1988, Cancer research.

[8]  J. Lankelma,et al.  Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and-sensitive cell lines , 1987, Cancer Chemotherapy and Pharmacology.

[9]  R. Jonker,et al.  Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry , 2004, Cancer Chemotherapy and Pharmacology.

[10]  Y. Sugiyama,et al.  Saturable Process Involved in Active Efflux of Vincristine as a Mechanism of Multidrug Resistance in P388 Leukemia Cells , 1989, Pharmaceutical Research.

[11]  G. Moore,et al.  Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. , 1979, Cancer research.

[12]  T. Maniatis,et al.  Identification of two distinct regulatory regions adjacent to the human β-interferon gene , 1983, Cell.

[13]  T. Tsuruo.  Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. , 1983, Cancer treatment reports.

[14]  T. Tsuruo,et al.  Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein. , 1988, Biochemical pharmacology.

[15]  H. Pollard,et al.  Doxorubicin resistance in P388 leukemia—evidence for reduced drug influx , 1989, International journal of cancer.

[16]  K. Janáček,et al.  Cell Membrane Transport , 1975, Springer US.

[17]  Y. Ostchega,et al.  Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Azzaria,et al.  Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance , 1989, Molecular and cellular biology.

[19]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Lankelma,et al.  Induction by verapamil of a rapid increase in ATP consumption in multidrug‐resistant tumor cells , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  V. Ling,et al.  Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies , 1985, Nature.

[22]  J. Riordan,et al.  Equilibrium, kinetic and photoaffinity labeling studies of daunomycin binding to P-glycoprotein-containing membranes of multidrug-resistant Chinese hamster ovary cells. , 1989, European journal of biochemistry.

[23]  J. Bulte,et al.  Monoclonal antibody JSB‐1 detects a highly conserved epitope on the P‐glycoprotein associated with multi‐drug‐resistance , 1988, International journal of cancer.

[24]  T. Tsuruo,et al.  Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. , 1989, Cancer research.

[25]  J. L. Biedler,et al.  Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. , 1970, Cancer research.

[26]  I. Pastan,et al.  ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[27]  I. Pastan,et al.  Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine. , 1989, The Journal of biological chemistry.

[28]  D. Housman,et al.  Isolation and expression of a complementary DNA that confers multidrug resistance , 1986, Nature.

[29]  J. Lankelma,et al.  Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient. , 1990, Biochimica et biophysica acta.

[30]  D. Housman,et al.  Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins , 1986, Cell.

[31]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[32]  S. Akiyama,et al.  Cytoplasmic orientation and two-domain structure of the multidrug transporter, P-glycoprotein, demonstrated with sequence-specific antibodies. , 1989, The Journal of biological chemistry.

[33]  J. B. Vermorken,et al.  The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. , 1990, British Journal of Cancer.

[34]  T. Skovsgaard.  Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. , 1978, Biochemical pharmacology.

[35]  J. Changeux,et al.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.

[36]  J. Lankelma,et al.  Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein binding. , 1987, Cancer letters.

[37]  M. Dalmark,et al.  A Fickian diffusion transport process with features of transport catalysis. Doxorubicin transport in human red blood cells , 1981, The Journal of general physiology.

[38]  T. Tsuruo,et al.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Koeller,et al.  Phase I study of vinblastine and verapamil given by concurrent iv infusion. , 1985, Cancer treatment reports.

[40]  P. Workman,et al.  Identification of anthracyclines and related agents that retain preferential activity over Adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A , 2008, Cancer Chemotherapy and Pharmacology.

[41]  J. Endicott,et al.  Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance , 1986, Nature.

[42]  J. Lankelma,et al.  A flow-through tissue culture system with fast dynamic response. , 1982, Analytical biochemistry.

[43]  D. Housman,et al.  Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. , 1990, Cancer research.

[44]  M. Dalmark.  Characteristics of doxorubicin transport in human red blood cells. , 1981, Scandinavian journal of clinical and laboratory investigation.

[45]  Michael M. Gottesman,et al.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.

[46]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[47]  A. Safa.  Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Yin,et al.  Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933 , 2004, Cancer Chemotherapy and Pharmacology.

[49]  T. Watanabe,et al.  Kinetic analysis of active efflux of vincristine from multidrug-resistant P388 leukemia cells. , 1987, Japanese journal of cancer research : Gann.

[50]  L. Helson.  Calcium channel blocker enhancement of anticancer drug cytotoxicity--a review. , 1984, Cancer drug delivery.

[51]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.

[52]  J. Changeux,et al.  Allosteric proteins and cellular control systems. , 1963, Journal of molecular biology.